{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T09:53:58Z","timestamp":1769075638808,"version":"3.49.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Badr University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>The aim of this work was to investigate homogeneity and stability of liver SUV in terms of different malignancies considering different body normalization schemes and blood glucose concentrations as well as PET\/CT imaging systems.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The study included 207 patients with four different types of cancers namely breast, lymphoma, lung, and bone-metastasis. Data acquisition was performed with GE Discovery IQ, Biograph mCT, uMI 550, and Ingenuity TF64 after a single intravenous injection of 194\u2009\u00b1\u200967.5 MBq of 18F-FDG.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In body weight normalization, SUVmax and SUVmean in bone-mets as well as SUVmean in lung patients were not statistically different among scanners especially for data corrected for glucose levels (<jats:italic>p\u2009=\u2009<\/jats:italic>0.062, 0.121, and 0.150, respectively). In SUVlbm derived from lung patients, there was no significant differences in Philips in comparison to GE and Siemens (both, <jats:italic>p\u2009&gt;\u2009<\/jats:italic>0.05) for data corrected and not corrected for glucose levels. In SUVbsa, the only non-significant difference revealed among scanners was in the measurements of SUVmean obtained from lung and bone-mets (<jats:italic>p\u2009=\u2009<\/jats:italic>0.107 and 0.114) both corrected for glucose levels. In SUVbmi, SUVmean of lung and bone-mets as well as SUVmax of bone-mets showed a non-significant differences among the four different scanning systems (<jats:italic>p\u2009=\u2009<\/jats:italic>0.303, 0.091, and 0.222, respectively) for data corrected for glucose levels.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Liver glucose correction needs further investigations in individual tumors but could be potentially affected by whether measurements are made on SUVmean versus SUVmax, body weight normalization, as well as the imaging system. As such, selection of normalization to body weight method should be carefully selected before clinical adoption and clinically adopted and body surface area would provide the highest correlation. As such, normalization of body weight should be carefully made before clinical adoption. SUVmean proves to be useful and stable metric when liver is corrected for blood glucose levels.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12149-024-01985-7","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T04:02:03Z","timestamp":1729051323000},"page":"176-188","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Estimation of liver standardized uptake value in F18-FDG PET\/CT scanning: impact of different malignancies, blood glucose level, body weight normalization, and imaging systems"],"prefix":"10.1007","volume":"39","author":[{"given":"Mohamed S.","family":"Abd-Elkader","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherif M.","family":"Elmaghraby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A.","family":"Abdel-Mohsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2087-5229","authenticated-orcid":false,"given":"Magdy M.","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"key":"1985_CR1","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00259-009-1297-4","volume":"37","author":"R Boellaard","year":"2010","unstructured":"Boellaard R, O\u2019Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET\/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181\u2013200.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1985_CR2","first-page":"784","volume":"45","author":"N Paquet","year":"2004","unstructured":"Paquet N, Albert A, Foidert J, Hustinx R. Within-patient variability of 18F-FDG: standardized uptake values in normal tissues. J Nucl Med. 2004;45:784\u20138.","journal-title":"J Nucl Med"},{"key":"1985_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s002590000421","volume":"28","author":"CD Ramos","year":"2001","unstructured":"Ramos CD, Erdi YE, Gonen M, Riedel E, Yeung HW, Macapinlac HA, et al. FDG-PET standardized uptake values in normal anatomic structures using iterative reconstructed segmented attenuation correction and filtered back-projection. Eur J Nucl Med. 2001;28:155\u201364.","journal-title":"Eur J Nucl Med"},{"key":"1985_CR4","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.rcl.2005.05.008","volume":"43","author":"AH Khandani","year":"2005","unstructured":"Khandani AH, Wahl RL. Applications of PET in liver imaging. Radiol Clin N Am. 2005;43:849\u201360.","journal-title":"Radiol Clin N Am"},{"key":"1985_CR5","first-page":"2058","volume":"45","author":"R Kumar","year":"2004","unstructured":"Kumar R, Xiu Y, Yu JQ, Takalkar A, El-Haddad G, Potenta S, et al. 18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. J Nucl Med. 2004;45:2058\u201362.","journal-title":"J Nucl Med"},{"key":"1985_CR6","first-page":"1030","volume":"39","author":"CG Diederichs","year":"1998","unstructured":"Diederichs CG, Staib L, Glatting G, Beger HG, Reske SN. FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med. 1998;39:1030\u20133.","journal-title":"J Nucl Med"},{"issue":"176","key":"1985_CR7","first-page":"180","volume":"196","author":"G Abikhzer","year":"2011","unstructured":"Abikhzer G, Alabed YZ, Azoulay L, Assayag J, Rush C. Altered hepatic metabolic activity in patients with hepatic steatosis on FDG-PET\/CT. AJR Am J Roentgenol. 2011;196(176):180.","journal-title":"AJR Am J Roentgenol"},{"key":"1985_CR8","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.clinimag.2011.02.005","volume":"35","author":"CY Lin","year":"2011","unstructured":"Lin CY, Lin WY, Lin CC, Shih CM, Jeng LB, Kao CH. The negative impact of fatty liver on maximum standard uptake value of liver on FDG PET. Clin Imaging. 2011;35:437\u201341.","journal-title":"Clin Imaging"},{"key":"1985_CR9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s11307-009-0258-4","volume":"12","author":"GG Bural","year":"2010","unstructured":"Bural GG, Torigian DA, Burke A, Houseni M, Alkhawaldeh K, Cucchiara A, et al. Quantitative assessment of the hepatic metabolic volume product in patients with diffuse hepatic steatosis and normal controls through use of FDG-PET and MR imaging: a novel concept. Mol Imaging Biol. 2010;12:233\u20139.","journal-title":"Mol Imaging Biol"},{"key":"1985_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s12149-009-0338-1","volume":"24","author":"K Kamimura","year":"2010","unstructured":"Kamimura K, Nagamachi S, Wakamatsu H, Higashi R, Ogita M, Ueno S, et al. Associations between liver (18)F fluoro-2- deoxy-D-glucose accumulation and various clinical parameters in a Japanese population: influence of the metabolic syndrome. Ann Nucl Med. 2010;24:157\u201361.","journal-title":"Ann Nucl Med"},{"key":"1985_CR11","first-page":"818","volume":"35","author":"Y Choi","year":"1994","unstructured":"Choi Y, Hawkins RA, Huang SC, Brunken RC, Hoh CK, Messa C, et al. Evaluation of the effect of glucose ingestion and kinetic model configurations of FDG in the normal liver. J Nucl Med. 1994;35:818\u201323.","journal-title":"J Nucl Med"},{"key":"1985_CR12","first-page":"1811","volume":"36","author":"T Torizuka","year":"1995","unstructured":"Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG PET. J Nucl Med. 1995;36:1811\u20137.","journal-title":"J Nucl Med"},{"key":"1985_CR13","first-page":"729","volume":"39","author":"LA Green","year":"1998","unstructured":"Green LA, Gambhir SS, Srinivasan A, Banerjee PK, Hoh CK, Cherry SR, et al. Noninvasive methods for quantitating blood timeactivity curves from mouse pet images obtained with fluorine-18- fluorodeoxyglucose. J Nucl Med. 1998;39:729\u201334.","journal-title":"J Nucl Med"},{"key":"1985_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.nucmedbio.2010.09.004","volume":"38","author":"K Kubota","year":"2011","unstructured":"Kubota K, Watanabe H, Murata Y, Yukihiro M, Ito K, Morooka M, et al. Effects of blood glucose level on FDG uptake by liver: a FDG-PET\/CT study. Nucl Med Biol. 2011;38:347\u201351.","journal-title":"Nucl Med Biol"},{"key":"1985_CR15","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1097\/RLU.0b013e3182872f0e","volume":"38","author":"D Groheux","year":"2013","unstructured":"Groheux D, Delord M, Rubello D, Colletti PM, Nguyen M-L, Hindie E. Variation of liver SUVon 18FDG-PET\/CTstudies in women with breast cancer. Clin Nucl Med. 2013;38:422\u20135.","journal-title":"Clin Nucl Med"},{"issue":"1","key":"1985_CR16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s41824-022-00142-5","volume":"6","author":"EM Badawe","year":"2022","unstructured":"Badawe EM, Abdel Gawad H, El-Nagdy MS, Khalil MM. Variations induced by body weight and background lesion normalization in standardized uptake value estimated by F18-FDG PET\/CT. Eur J Hybrid Imaging. 2022;6(1):22.","journal-title":"Eur J Hybrid Imaging"},{"key":"1985_CR17","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1038\/sj.bjc.6604330","volume":"98","author":"F Castell","year":"2008","unstructured":"Castell F, Cook GJR. Quantitative techniques in 18FDG PET scanning in oncology. Br J Cancer. 2008;98:1597\u2013601.","journal-title":"Br J Cancer"},{"key":"1985_CR18","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.rcl.2004.08.010","volume":"42","author":"P Acton","year":"2004","unstructured":"Acton P, Zhuang H, Alavi A. Quantification in PET. Radiol Clin N Am. 2004;42:1055\u201362.","journal-title":"Radiol Clin N Am"},{"key":"1985_CR19","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s12149-010-0359-9","volume":"24","author":"J Claeys","year":"2010","unstructured":"Claeys J, Mertens K, D\u2019Asseler Y, Goethals I. Normoglycemic plasma glucose levels affect F-18 FDG uptake in the brain. Ann Nucl Med. 2010;24:501\u20135.","journal-title":"Ann Nucl Med"},{"key":"1985_CR20","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s11307-006-0064-1","volume":"8","author":"E Turcotte","year":"2006","unstructured":"Turcotte E, Leblanc M, Carpentier A, Benard F. Optimization of whole-body positron emission tomography imaging by using delayed 2-deoxy-2-[F-18] fluoro-D: -glucose injection following I.V. insulin in diabetic patients. Mol Imaging Biol. 2006;8:348\u201354.","journal-title":"Mol Imaging Biol."},{"key":"1985_CR21","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s00259-003-1127-z","volume":"30","author":"NC Krak","year":"2003","unstructured":"Krak NC, van der Hoeven JJM, Hoekstra OS, Twisk JWR, van der Wall E, Lammertsma AA. Measuring [(18)F]FDG uptake in breast cancer during chemotherapy: comparison of analytical methods. Eur J Nucl Med Mol Imaging. 2003;30:674\u201381.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1985_CR22","first-page":"1186","volume":"38","author":"N Avril","year":"1997","unstructured":"Avril N, Bense S, Ziegler SI, et al. Breast imaging with fluorine-18-FDG PET: quantitative image analysis. J Nucl Med. 1997;38:1186\u201391.","journal-title":"J Nucl Med"},{"key":"1985_CR23","first-page":"1659","volume":"46","author":"CY Wong","year":"2005","unstructured":"Wong CY, Thie J, Parling-Lynch KJ, et al. Glucose-normalized standardized uptake value from 18F-FDG PET in classifying lymphomas. J Nucl Med. 2005;46:1659\u201363.","journal-title":"J Nucl Med"},{"key":"1985_CR24","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s00259-004-1626-6","volume":"31","author":"A Stahl","year":"2004","unstructured":"Stahl A, Ott K, Schwaiger M, Weber WA. Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET. Eur J Nucl Med Mol Imaging. 2004;31:1471\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1985_CR25","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/MNM.0b013e32832bdc80","volume":"30","author":"D Vriens","year":"2009","unstructured":"Vriens D, de Geus-Oei L, van Laarhoven HW, et al. Evaluation of different normalization procedures for the calculation of the standardized uptake value in therapy response monitoring studies. Nucl Med Commun. 2009;30:550\u20137.","journal-title":"Nucl Med Commun"},{"key":"1985_CR26","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s12149-009-0263-3","volume":"23","author":"B Sanghera","year":"2009","unstructured":"Sanghera B, Emmott J, Wellsted D, Chambers J, Wong W. Influence of N-butylscopolamine on SUV in FDG PET of the bowel. Ann Nucl Med. 2009;23:471\u20138.","journal-title":"Ann Nucl Med"},{"key":"1985_CR27","first-page":"784","volume":"45","author":"N Paquet","year":"2004","unstructured":"Paquet N, Albert A, Foidart J, Hustinx R. Within-patient variability of 18F-FDG: standardized uptake values in normal tissues. J Nucl Med. 2004;45:784\u20138.","journal-title":"J Nucl Med"},{"key":"1985_CR28","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.nucmedbio.2008.02.007","volume":"35","author":"M Hadi","year":"2008","unstructured":"Hadi M, Bacharach SL, Whatley M, et al. Glucose and insulin variations in patients during the time course of a FDG-PET study and implications for the \u201cglucose-corrected\u201d SUV. Nucl Med Biol. 2008;35:441\u20135.","journal-title":"Nucl Med Biol"},{"key":"1985_CR29","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s00259-018-4194-x","volume":"46","author":"M Eskian","year":"2019","unstructured":"Eskian M, Alavi A, Khorasanizadeh M, Viglianti BL, Jacobsson H, et al. Effect of blood glucose level on standardized uptake value (SUV) in 18F-FDG PET-scan: a systematic review and meta-analysis of 20,807 individual SUV measurements. Eur J Nucl Med Mol Imaging. 2019;46:224\u201337.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1985_CR30","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1097\/MNM.0b013e3282f9b5a0","volume":"29","author":"B Degirmenci","year":"2008","unstructured":"Degirmenci B, Wilson D, Laymon CM, Becker C, Mason NS, Bencherif B, Agarwal A, Luketich J, Landreneau R, Avril N. Standardized uptake value-based evaluations of solitary pulmonary nodules using F-18 fluorodeoxyglucose-PET\/computed tomography. Nucl Med Commun. 2008;29:614\u201322.","journal-title":"Nucl Med Commun"},{"key":"1985_CR31","first-page":"1059","volume":"47","author":"LK Shankar","year":"2006","unstructured":"Shankar LK, Hoffman JM, Bacharach S, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med. 2006;47:1059\u201366.","journal-title":"J Nucl Med"},{"key":"1985_CR32","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1007\/s00259-008-0874-2","volume":"35","author":"R Boellaard","year":"2008","unstructured":"Boellaard R, Oyen WJG, Hoekstra CJ, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging. 2008;35:2320\u201333.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1985_CR33","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1007\/s00330-015-3659-6","volume":"25","author":"G Keramida","year":"2015","unstructured":"Keramida G, Dizdarevic S, Bush J, Peters AM. Quantification of tumour 18F-FDG uptake: normalise to blood glucose or scale to liver uptake? Eur Radiol. 2015;25:2701\u20138.","journal-title":"Eur Radiol."},{"key":"1985_CR34","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2967\/jnmt.119.233353","volume":"48","author":"I Sarikaya","year":"2020","unstructured":"Sarikaya I, Albatineh AN, Sarikaya A. Revisiting weight-normalized SUV and lean-body-mass-normalized SUV in PET studies. J Nucl Med Technol. 2020;48:163\u20137.","journal-title":"J Nucl Med Technol"},{"key":"1985_CR35","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1148\/radiology.189.3.8234714","volume":"189","author":"KR Zasadny","year":"1993","unstructured":"Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine 18]fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology. 1993;189:847\u201350.","journal-title":"Radiology"},{"key":"1985_CR36","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, Stroobants S, Delbeke D, Donohoe KJ, Holbrook S, Graham MM, Testanera G, Hoekstra OS, Zijlstra J, Visser E, Hoekstra CJ, Pruim J, Willemsen A, Arends B, Kotzerke J, Bockisch A, Beyer T, Chiti A. European Association of Nuclear Medicine (EANM) FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"10","key":"1985_CR37","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.ejca.2013.02.025","volume":"49","author":"J-Y Lee","year":"2013","unstructured":"Lee J-Y, Jeon I, Lee JM, Yoon J-M, Park SM. Diabetes mellitus as an independent risk factor for lung cancer: a meta-analysis of observational studies. Eur J Cancer. 2013;49(10):2411\u201323.","journal-title":"Eur J Cancer."},{"issue":"6","key":"1985_CR38","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3892\/mco.2017.1224","volume":"6","author":"K Kurishima","year":"2017","unstructured":"Kurishima K, Watanabe H, Ishikawa H, Satoh H, Hizawa N. Survival of patients with lung cancer and diabetes mellitus. Mol Clin Oncol. 2017;6(6):907\u201310.","journal-title":"Mol Clin Oncol"},{"issue":"3","key":"1985_CR39","doi-asserted-by":"publisher","first-page":"590","DOI":"10.2337\/diacare.28.3.590","volume":"28","author":"GC Hall","year":"2005","unstructured":"Hall GC, Roberts CM, Boulis M, Mo J, MacRae KD. Diabetes and the risk of lung cancer. Diabetes Care. 2005;28(3):590\u20134.","journal-title":"Diabetes Care"},{"key":"1985_CR40","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0969-8051(98)00038-9","volume":"25","author":"A Waki","year":"1998","unstructured":"Waki A, Kato H, Yano R, Sadato N, Yokoyama A, Ishii Y, Yonekura Y, Fujibayashi Y. The importance of glucose transport activity as the rate-limiting step of 2-deoxyglucose uptake in tumor cells in vitro. Nucl Med Biol. 1998;25:593\u20137.","journal-title":"Nucl. Med. Biol."},{"key":"1985_CR41","doi-asserted-by":"publisher","first-page":"E508","DOI":"10.1152\/ajpendo.2000.279.3.E508","volume":"279","author":"D Rivenzon-Segal","year":"2000","unstructured":"Rivenzon-Segal D, Rushkin E, Polak-Charcon S, Degani H. Glucose transporters and transport kinetics in retinoic acid-differentiated t47d human breast cancer cells. Am J Physiol Endocrinol Metab. 2000;279:E508\u201319.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"1985_CR42","first-page":"77","volume":"355","author":"M Hatanaka","year":"1974","unstructured":"Hatanaka M. Transport of sugars in tumor cell membranes. Biochim Biophys Acta. 1974;355:77\u2013104.","journal-title":"Biochim Biophys Acta"},{"key":"1985_CR43","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature13110","volume":"508","author":"K Irsoy","year":"2014","unstructured":"Irsoy K, Possemato R, Lorbeer FK, Bayraktar EC, Thiru P, Yucel B, Wang T, Chen WW, Clish CB, Sabatini DM. Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature. 2014;508:108\u201312.","journal-title":"Nature"}],"updated-by":[{"DOI":"10.1007\/s12149-025-02019-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T00:00:00Z","timestamp":1738454400000}}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-024-01985-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-024-01985-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-024-01985-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T07:06:57Z","timestamp":1738825617000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-024-01985-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1985"],"URL":"https:\/\/doi.org\/10.1007\/s12149-024-01985-7","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s12149-025-02019-6","asserted-by":"object"}]},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,16]]},"assertion":[{"value":"26 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Supplementary file was missing from this article and has now been uploaded.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12149-025-02019-6","URL":"https:\/\/doi.org\/10.1007\/s12149-025-02019-6","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All ethical approvals were communicated to conduct the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All subjects or legal representatives gave written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}